Scientists investigate Africa's COVID-19 mystery: why were cases so mild?

NCT ID NCT05973084

First seen May 28, 2026

Summary

This study in Malawi aims to understand why COVID-19 was much less severe there than in Europe and the Americas. Researchers will follow 1500 people, including those infected and their household contacts, to see how factors like prior infections, nutrition, and immune responses affect transmission and vaccine effectiveness. The goal is to uncover what protected the population, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS COV 2 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BU School of Public Health, Global Health Department

    ACTIVE_NOT_RECRUITING

    Boston, Massachusetts, 02118, United States

  • Health center

    RECRUITING

    Blantyre, Malawi

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could reveal why COVID-19 was milder in sub-Saharan Africa, potentially guiding future pandemic responses and vaccine strategies.

What could go wrong

This is an observational study, not a treatment trial. It may not find clear answers, and results may not apply to other regions or future variants.

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.